CoChat
Sign Up
Cited by 322CAR-T cell therapy researchImmunotherapy and Immune ResponsesVirus-based gene therapy research

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Open access
Abou-el-Enein, Mohamed, Elsallab, Magdi, Feldman, Steven A., Fesnak, Andrew D., Heslop, Helen E., Marks, Peter, Till, Brian G., Bauer, Gerhard +1 more·2021·Blood Cancer Discovery
DOI 10.1158/2643-3230.bcd-21-0084PMC PMC8462122

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Manufacturing Practice (GMP)–compliant closed and automated systems to ensure reproducibility and to meet the increased demand for patients with cancer. In this review, we describe current CAR T cell clinical manufacturing models and discuss emerging technologic advances that embrace scaling and production optimization. We summarize measures being used to shorten CAR T cell manufacturing times and highlight regulatory challenges to scaling production for clinical use. Significance: As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development. This review provides a critical appraisal of these technologies, which can be leveraged to scale and optimize the production of next-generation CAR T cells. See related video: https://aacrjournals.org/content/webinar-car-t-cell-manufacturing

AI snapshot

Written from the paper’s full text.

TL;DR

This review summarizes current autologous CAR T-cell manufacturing and emerging closed, automated, and allogeneic platforms intended to scale production. It highlights efforts to shorten manufacturing and QC times while noting regulatory, cost, and variability barriers.

Key findings

  • As of April 2021, five commercial CAR T-cell therapies are approved; approved products are second-generation CARs incorporating CD28 or CD137 (4-1BB) co-stimulation, and they achieved complete responses in 32–67% of lymphoma patients, with better CR rates in leukemia.
  • By 2026, commercial CAR T-cell therapies are projected to comprise the largest share of oncology drug sales in pediatric and young adult patients with ALL (44%) and adults with DLBCL (46%).
  • Rapid manufacturing approaches include the FasT CAR platform, which reduced cell culture time to less than 24 hours; in 10 adolescent and adult patients with CD19+ relapsed/refractory B-ALL, 10/10 (100%) achieved CR on day 15, with only one patient experiencing CRS. Sleeping Beauty–generated CAR T cells shortened ex vivo culture to 14 days, with median CAR expression upon infusion of 86% (range 19%–97%) in six patients.
  • Non-viral piggyBac transfection was associated with lymphoma arising from piggyBac-transfected CAR T cells in two of nine patients with relapsed or refractory B-cell malignancies who achieved complete remission; analysis showed increased transgene copy numbers but no integration in typical oncogenes.

Methods

  • Narrative review of clinical CAR T-cell manufacturing models, emerging scaling and automation technologies, genetic modification strategies, quality control, and regulatory considerations.
  • Synthesizes published literature, clinical trial reports, and regulatory documents; no primary experimental data or systematic search methodology is described.

Limitations

  • The paper does not state limitations of the review itself. It extensively discusses field limitations: variability in autologous starting material, open/manual processing, batch-to-batch variation, contamination and human error, viral vector cost and time, expensive closed systems with single-product runs and supply-chain risk, and regulatory discrepancies.
  • Evident from the text: as a narrative review, it lacks systematic search criteria, meta-analysis, and primary data; cited trial results and projections come from external sources.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-21-0084

Cites

143 of 144 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

61 of 111 cited sources checked · 14 supported · 1 flagged · accuracy not yet measured

  • Premisecitation

    In a Phase I clinical trial, an autologous bispecific CD19/CD22-targeted CAR T cell therapy was manufactured using the FasT CAR platform, reducing cell culture time to less than 24 hours.

    “For a Phase I clinical trial, researchers manufactured an autologous, bispecific CD19/CD22-targeted CAR T cell therapy using the FasT CAR platform, reducing cell culture time to less than 24 hours (117,118).”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [117] Lino, 2018, Delivering CRISPR: a review of the challenges and approaches, Drug Deliv source

      The Introduction discusses earlier gene-therapy trials, and the delivery-method sections discuss CRISPR/Cas9 rather than CAR T-cell manufacturing. Searches for FasT CAR, CD19/CD22, the Phase I trial, and a culture time under 24 hours found no passage addressing the claimed therapy or manufacturing time in our copy. (LLM, conf=0.77)

      Experimental — accuracy not yet measured
    • cites [118] Roth, 2018, Reprogramming human T cell function and specificity with non-viral genome targeting, Nature source

      The Abstract (page unavailable) describes preclinical engineering of NY-ESO-1-targeted TCR cells, not a Phase I trial of bispecific CD19/CD22 CAR T cells. The Methods (Primary human T cell culture, page unavailable) specify two days of stimulation before electroporation, and the Abstract reports ten days of expansion—not cell culture lasting less than 24 hours. (LLM, conf=0.84)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    The composition of autologous starting material from cancer patients is highly variable, influenced by patient age and defects due to underlying disease or pre-treatment with lymphotoxic agents.

    “However, the composition of autologous starting material from cancer patients is highly variable, influenced by patient age and defects due to underlying disease or pre-treatment with lymphotoxic agents (35-38).”
    Quote in the paperSubstantial claim3 of 4 sources checked
    • cites [35] Singh, 2016, Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies, Sci Transl Med source
    • cites [36] Fesnak, 2020, The challenge of variability in chimeric antigen receptor T cell manufacturing, Regen Eng Transl Med source

      The “Pre-collection source of variability” section identifies underlying disease and prior treatment as drivers of variation in autologous starting material, and describes chemotherapy-associated T-cell depletion and growth defects. It treats age more cautiously, saying it is likely to be a source of variability; the claim presents age as an established influence. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [37] Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability, J Clin Invest source

      The Results describe differences in apheresis starting-material T cells among pediatric patients with relapsed or refractory ALL and compared with healthy donors. The Discussion suggests that recent cytotoxic therapy may contribute to T-cell damage, but does not establish that patient age or underlying disease independently determines starting-material composition. The claim also generalizes this pediatric ALL finding to cancer patients broadly. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [38] Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature source

      The Methods section ('Patient samples' and 'CAR T-cell manufacturing and correlative studies'; page not available) describes obtaining autologous T cells but does not assess variability in starting-material composition. Searches for patient age, underlying disease, and prior lymphotoxic treatment found no passage linking those factors to that composition. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
  • Premisecitation

    Most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing.

    “First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
    Quote in the paperSubstantial claim9 of 10 sources checked
    • cites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med source
    • cites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med source
    • cites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med source
    • cites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood source
    • cites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol source
    • cites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet source
    • cites [15] Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients, J Clin Invest source
    • cites [16] Neelapu, 2017, Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma, N Engl J Med source
    • cites [17] Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med source
    • cites [18] Wang, 2020, KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma, N Engl J Med source
  • Premisecitation

    All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals.

    “All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
    Quote in the paperNot a substantial claim6 of 7 sources checked
    • cites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med source

      The paper states that the CTL019 receptor includes a CD137 (4-1BB) signaling domain, and the Results report substantial expansion of CTL019 cells in two children. It does not establish that all approved CAR T-cell products are second-generation CARs or that they all incorporate CD28 or CD137; the Methods describe this as a phase 1 trial, not a survey of approved products. No page numbers are available in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med source

      The Introduction identifies the study’s CD28-containing CAR as second-generation, and the Discussion describes a second-generation CAR containing 4-1BB. Neither section establishes that all approved CAR T-cell products use one of these designs; the paper discusses clinical studies rather than approved products. Page numbers are not available in our copy. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med source

      The Discussion (page unavailable) identifies the authors’ CD137 (4-1BB) CAR as second-generation and mentions a separate CD28-linked CAR trial. The paper supports the role of costimulation in expansion and persistence, but it does not assess approved products or establish that all approved CAR T-cell products have either design. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood source

      The Methods (page not provided) describe this study’s anti-CD19 CAR as containing CD28 and CD3ζ signaling domains, and the Results and discussion report activity in one treated patient. The paper does not establish that all approved CAR T-cell products use CD28 or CD137, or that these signals are essential for effector and memory-cell expansion and persistence. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol source

      The ‘Anti-CD19 CAR T Cells Generated From PBMCs of Heavily Treated Patients’ section states that the CAR used in this study contained a CD28 costimulatory moiety. The paper does not establish that all approved CAR T-cell products are second-generation CARs or that they use either CD28 or CD137; it describes this study’s construct, not the approved-product class. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet source

      The Methods describe a trial CAR incorporating a CD28 signalling domain, and the Discussion mentions CD19-CARs incorporating 4-1BB. Neither section establishes that all approved CAR T-cell products are second-generation or use one of those domains; this phase 1 trial is not a survey of approved products. No page numbers are available in our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [15] Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients, J Clin Invest source
  • Premisecitation

    In 2011, the FDA published a study that acknowledged rapid sterility tests as an alternative.

    “In 2011, the FDA published a study that acknowledged rapid sterility tests as an alternative (122).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [122] Pampusch, 2020, Rapid transduction and expansion of transduced T cells with maintenance of central memory populations, Mol Ther Methods Clin Dev source

      The Materials and Procedure passages describe T-cell transduction and expansion, not sterility-testing policy. Searches for rapid sterility tests and FDA guidance found no passage in our copy addressing a 2011 FDA study or its acceptance of such tests as an alternative. (LLM, conf=0.75)

      Experimental — accuracy not yet measured
  • May combine two claims. 36
  • Classified as probably not a substantial claim. 20

  • May combine two claims.

    Premisecitation

    Viral vectors have proven efficient in achieving stable gene transfer, but their requisite extensive safety testing adds to the cost and time to develop and manufacture CAR T cell products.

    “Although viral vectors have proven efficient in achieving stable gene transfer, their requisite extensive safety testing adds to the cost and time to develop and manufacture CAR T cell products (27,28).”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [27] Wang, 2015, Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor, J Immunother source

      The Abstract describes successful CAR T-cell engineering with retroviral vectors, and the Results section on vector quality reports an array of release tests, including tests for sterility and replication-competent retrovirus (page not provided). The paper does not say that safety testing itself increases the cost or time of developing and manufacturing CAR T-cell products; its Discussion links cost reduction to improvements in vector production instead. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [28] van der Loo, 2012, Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection, Gene Ther source

      The Results (cGMP production; page unavailable) document extensive safety testing of the manufactured viral vectors. The Introduction also says that certifying stable producer cell banks is lengthy and costly, but it does not establish that safety testing itself adds cost and time to CAR T-cell product development or manufacturing. The paper concerns clinical-grade vector production, not CAR T-cell products. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Transduction of cells other than T lymphocytes, such as malignant blasts, has been observed, creating the risk of engineering CARs into cancer cells and giving rise to CAR-resistant tumor cells.

    “Further, transduction of cells other than T lymphocytes (e.g. malignant blasts) has been observed, creating the risk of engineering CARs into cancer cells, giving rise to CAR-resistant tumor cells (48).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [48] Ruella, 2018, Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell, Nat Med source

  • May combine two claims.

    Premisecitation

    Most clinical protocols and all commercially approved therapies have relied on viral vectors to deliver CAR transgenes into T cells.

    “Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
    Quote in the paperSubstantial claim7 of 9 sources checked
    • cites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med source

      The Methods describe this clinical protocol as using a lentiviral vector, and the Abstract says CTL019 was expressed using lentiviral-vector technology. This supports the paper as an example of a clinical protocol using a viral vector, but it does not establish that most protocols or all commercially approved therapies use viral vectors. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med source

      Materials and Methods (Generation of 19-28z CAR modified T cells; page unavailable) says the trial's T cells were transduced with gammaretroviral 19-28z supernatant, supporting this protocol as an example of viral-vector delivery. The paper does not establish that most clinical protocols or all commercially approved CAR-T therapies use viral vectors. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med source

      The Methods (Study Procedures; page unavailable) describe this clinical trial's use of a lentiviral vector, and the Discussion says the authors used HIV-derived lentiviral vectors. The paper therefore supports an example of a clinical protocol using viral delivery, but it does not establish that most protocols or all commercially approved therapies did so. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood source

      The Methods (page not provided) describe a clinical trial that used a retroviral vector to deliver an anti-CD19 CAR into T cells. This supports the paper as an example of a viral-vector clinical protocol, but it does not establish that most protocols or all commercially approved therapies used viral vectors. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol source

      The Preparation of Anti-CD19 CAR T Cells and Ex Vivo Assays section (page unavailable) says this clinical study used a gammaretroviral vector encoding the CAR, supporting it as an example of viral-vector delivery. The paper does not establish that most clinical protocols used viral vectors or that all commercially approved therapies did. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet source

      The Methods > Procedures section (page not provided) says this clinical trial used a retroviral vector to manufacture CD19-CAR T cells. It does not establish that most clinical protocols or all commercially approved CAR T-cell therapies use viral vectors. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [24] Casati, 2013, Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients, Cancer Immunol Immunother source

      The Introduction (page unavailable) describes retroviral transduction as a current standard T-cell protocol, and Materials and methods (page unavailable) reports using a retroviral vector. But the vector in this study delivered a TCR, not a CAR; the paper does not establish that most CAR clinical protocols or all commercially approved CAR therapies used viral vectors. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [25] Zufferey, 1997, Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo, Nat Biotechnol source
    • cites [26] Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat Med source

  • May combine two claims.

    Premisecitation

    Fully automated closed processes eliminate any handling of the product during manufacturing but are restricted to a single product in each production run.

    “Fully automated closed processes eliminate any handling of the product during manufacturing but are restricted to a single product in each production run (77-79).”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites [77] Mock, 2016, Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy, Cytotherapy source

      The Introduction and Discussion (page numbers unavailable) describe automated processing in a closed, single-use tubing set and a single container. But the Discussion says manipulation is minimal, not eliminated, and Table S1 lists hands-on steps during the run. The paper does not establish that the system is restricted to one product per production run. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [78] Jackson, 2020, Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma, Front Immunol source

      The Introduction describes CliniMACS Prodigy as a closed automated CAR-T manufacturing system, and the Discussion reports manufacturing with a GMP-compliant closed system. Neither passage says that the product requires no handling during manufacturing or that a production run is restricted to one product; searches for handling and per-run capacity did not establish those claims. Our copy provides no page numbers for these passages. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [79] Alzubi, 2021, Automated generation of gene-edited CAR T cells at clinical scale, Mol Ther Methods Clin Dev source

      The Introduction and Results describe an automated, closed CAR T-cell manufacturing process. They do not say that it eliminates all product handling or that such processes are restricted to one product per production run; the Results describe product transfer and in-process sampling. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The presence of MDSCs and monocytes can hamper the ex vivo activation and expansion of T cells, and other contaminants such as granulocytes and red blood cells suppress T cell proliferation.

    “The presence of MDSCs and monocytes can hamper the ex vivo activation and expansion of T cells (40,42-44). Other cellular contaminants such as granulocytes and red blood cells suppress T cell proliferation (45,46).”
    Quote in the paperSubstantial claim3 of 6 sources checked
    • cites [40] Davis, 2017, Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in non-Hodgkin lymphoma (NHL), Cytotherapy source
    • cites [42] Stroncek, 2016, Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells, Cytotherapy source

      The Discussion reports that monocytes and granulocytes in starting PBMC concentrates inhibited CAR T-cell expansion and describes MDSCs as capable of inhibiting T-cell proliferation. It does not establish impaired T-cell activation or suppression by red blood cells. The printed sentence attaches a separate set of citations to the red-blood-cell claim, so this paper most directly supports the expansion portion of the first clause. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [43] Elavia, 2019, Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics, Transfusion source
    • cites [44] Noaks, 2021, Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing, Mol Ther Methods Clin Dev source

      The Discussion (page unavailable) says monocytes can inhibit T-cell activation and expansion, and the Results report improved activation after monocyte removal in Dynabead-stimulated cultures. The source does not establish the claim about MDSCs. The separate sentence about granulocytes and red blood cells carries different citations, so it is not attributed to this source. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [45] Long, 2014, T-cell suppression by red blood cells is dependent on intact cells and is a consequence of blood bank processing, Transfusion source
    • cites [46] Munder, 2006, Suppression of T-cell functions by human granulocyte arginase, Blood source

  • May combine two claims.

    Premisecitation

    Recovery and viability of PBMCs are significantly reduced after freezing and thawing compared to fresh apheresis products, but recovery of mononuclear cells after thawing is sufficient for consistent manufacturing of CAR T cells without evidence of significant differences in expansion, transduction efficiency or overall subset composition.

    “For instance, Panch et al. showed recovery and viability of PBMCs was significantly reduced after freezing and thawing compared to fresh apheresis products (39). Nevertheless, the recovery of mononuclear cells after thawing was sufficient for consistent manufacturing of CAR T cells, without evidence of significant differences in expansion, transduction efficiency or overall subset composition (39)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [39] Panch, 2019, Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics, Mol Ther source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Autologous CAR T cells have sometimes suffered manufacturing delays and, in some instances, had difficulty meeting target doses in commercial production.

    “Despite clinical success, autologous CAR T cells have sometimes suffered manufacturing delays and, in some instances, had difficulty meeting target doses in commercial production (23).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [23] Levine, 2017, Global manufacturing of CAR T cell therapy, Mol Ther Methods Clin Dev source

      The sections on scaling manufacturing and ensuring product quality discuss potential challenges, but do not report manufacturing delays or instances in which commercial production failed to meet target CAR T-cell doses. Searches for delays, dose, and target specifications found no passage establishing those events; the target-specifications passage concerns viral vector production instead. (LLM, conf=0.75)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Interpretationcitation

    Moving toward functionally closed and fully automated manufacturing platforms may enable production scalability and reduce potential human error.

    “Moving toward functionally closed and fully automated manufacturing platforms may enable production scalability and reduce potential human error (71).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [71] Fritsche, 2020, Toward an optimized process for clinical manufacturing of CAR-treg cell therapy, Trends Biotechnol source

      The passage labeled Abstract (page unavailable) describes a move toward nearly closed, (semi)automatic systems and says these reduce costs and batch-to-batch variability. It does not say that such platforms enable production scalability or reduce human error; its separate discussion of scaling up concerns medium supply. (LLM, conf=0.82)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    CAR T-cells elicited complete responses in 32-67% of lymphoma patients and showed better complete response rates in patients with leukemia.

    “These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
    Quote in the paperNot a substantial claim3 of 4 sources checked
    • cites [16] Neelapu, 2017, Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma, N Engl J Med source

      The Results > Efficacy section reports a 54% complete response rate in 101 patients with refractory large B-cell lymphoma, which falls within the cited 32–67% range. This paper does not establish that range across lymphoma patients or report better complete response rates in patients with leukemia. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [17] Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med source

      The Efficacy section (p. 4) reports complete responses in 40% of treated adults with diffuse large B-cell lymphoma, including 32% at month 3. The paper does not report a 67% lymphoma complete-response rate. It describes high efficacy in children and young adults with leukemia (p. 2), but does not establish that their complete-response rate was higher. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [18] Wang, 2020, KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma, N Engl J Med source

      The Results > Efficacy section reports a 67% complete-response rate among 60 treated patients with relapsed or refractory mantle-cell lymphoma. It does not establish the 32% lower end of the range or compare complete-response rates with those in leukemia patients. Page numbers are not available in our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [19] Cohen, 2019, B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma, J Clin Invest source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Five CAR T cell products are approved for commercial use and available on the U.S. market: three for B-cell leukemia and lymphoma, one for mantle cell lymphoma, and one for multiple myeloma.

    “Currently, five CAR T cell products are approved for commercial use and available on the U.S. market, three for B-cell leukemia and lymphoma (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel), one for mantle cell lymphoma (brexucabtagene autoleucel), and one for multiple myeloma (idecabtagene vicleucel) (2-8).”
    Quote in the paperNot a substantial claim1 of 7 sources checked
    • cites [2] Elsallab, 2020, CAR T cell product performance in haematological malignancies before and after marketing authorisation, Lancet Oncol source

      The Introduction identifies tisagenlecleucel and axicabtagene ciloleucel as approved in the USA for B-cell leukaemia or lymphoma indications. The Conclusion calls them the two approved products discussed in this 2020 paper. Our copy does not support the claim that five products were available on the U.S. market, or the stated approvals for the other three products. (LLM, conf=0.90)

      Experimental — accuracy not yet measured
    • cites [3] Abramson, 2020, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, Lancet source
    • cites [4] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [5] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [6] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [7] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [8] U.S. Food and Drug Administration, 2020, Center for Biologics Evaluation and Research

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In ten adolescent and adult patients with CD19+ relapsed/refractory B-ALL who received CD19 FasT CAR T cells, 10/10 (100%) achieved CR on day 15 after infusion, with only one patient experiencing CRS.

    “On day 15 after cell infusion, 10/10 (100%) patients achieved CR, with only one patient experiencing CRS (118).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [118] Roth, 2018, Reprogramming human T cell function and specificity with non-viral genome targeting, Nature source

      The Abstract describes NY-ESO-1 TCR-engineered cells reducing tumour burden in treated animals, and Extended Data Figure 10 describes a mouse melanoma model; neither reports outcomes for patients receiving CD19 FasT CAR T cells. Searches for the day-15 10/10 complete-remission result and cytokine release syndrome found no passage addressing those claims. Page numbers were not available in our copy. (LLM, conf=0.76)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    A similar clinical trial phase structure exists in the European Union, although some GMP regulations are stricter in Europe.

    “A similar clinical trial phase structure exists in the European Union, although some GMP regulations are stricter in Europe (132,133).”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [132] Cerignoli, 2018, In vitro immunotherapy potency assays using real-time cell analysis, PLoS One source

      The Introduction and Discussion discuss immunotherapy potency assays during development and manufacturing, but neither describes EU clinical trial phases or compares European GMP requirements with those elsewhere. Searches for the EU trial-phase structure and stricter GMP regulations found no passage addressing either claim. (LLM, conf=0.74)

      Experimental — accuracy not yet measured
    • cites [133] Kiesgen, 2021, Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity, Nat Protoc source

      The Introduction section on potency assays describes requirements by clinical-study phase but does not compare EU and US trial structures. Searches for European clinical-trial phases and stricter European GMP regulations found no passage addressing either comparison in our copy. (LLM, conf=0.76)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Several ranges/measures exist to determine total T cell number via CD3 expression, characterize CD4+ and CD8+ subsets, detect transduced and not transduced cells, and identify contaminating cell subsets such as monocytes/macrophages (CD14).

    “Several ranges/measures exist to determine the total T cell number via CD3 expression, to characterize the CD4+ and CD8+ subsets within this population (54), to detect transduced and not transduced cells, and to identify any contaminating cell subsets, such as monocytes/macrophages (CD14) (44).”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [54] Shah, 2020, CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T cell potency and toxicity: updated results from a phase I anti-CD22 CAR T cell trial, J Clin Oncol source
    • cites [44] Noaks, 2021, Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing, Mol Ther Methods Clin Dev source

  • May combine two claims.

    Premisecitation

    Disadvantages of non-viral vector and DNA transfection systems include process complexity, need for significant method optimization to overcome low efficiency of CAR expression, need for cell sorting post-engineering, and significant cell loss during gene delivery.

    “Disadvantage of these systems include process complexity, need for significant method optimization to overcome low efficiency of CAR expression, need for cell sorting post-engineering (Table S1) and significant cell loss during gene delivery (106).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [106] Sherba, 2020, The effects of electroporation buffer composition on cell viability and electro-transfection efficiency, Sci Rep source

  • May combine two claims.

    Interpretationcitation

    Applying CRISPR/Cas with non-viral delivery of template DNA to eliminate large genes or for orthotopic placement of transgenic constructs could reduce the potential of off-target effects.

    “Applying CRISPR/Cas with non-viral delivery of template DNA to eliminate large genes (145) or for orthotopic placement of transgenic constructs (146) could also reduce the potential of off-target effects.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [145] Wang, 2019, A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies, Cytotherapy source
    • cites [146] Harrison, 2017, Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities, Cytotherapy source

      The Introduction defines cell and gene therapies, and the Management of challenging value chains section discusses transfection as a manufacturing step. Neither passage addresses CRISPR/Cas, non-viral template delivery, deletion of large genes, orthotopic placement, or off-target effects; searches for those terms found no relevant passage in our copy. (LLM, conf=0.75)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    A U.S. company that seeks to manufacture CAR T-cells in the U.S. and E.U. must comply with both sets of regulations and work with strict oversight from both the FDA and EMA to meet respective manufacturing standards.

    “A U.S. company that seeks to manufacture CAR T-cells in the U.S. and E.U. must comply with both sets of regulations and work with strict oversight from both the FDA and the European Medicines Agency (EMA) to meet respective manufacturing standards (133,135,136).”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [133] Kiesgen, 2021, Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity, Nat Protoc source

      The Introduction’s “Potency assays for clinical cell therapy products” section describes requirements for potency testing and discusses FDA-approved CAR T-cell products. It does not address EMA oversight or say that a U.S. company manufacturing in both the U.S. and E.U. must comply with both sets of manufacturing regulations. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [135] Digiusto, 2018, Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility, Cytotherapy source
    • cites [136] Abou-El-Enein, 2013, Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs, Cytotherapy source

  • May combine two claims.

    Premisecitation

    Decentralized manufacturing in multiple small facilities is appealing, but new models of production scaling that rely on this approach remain a challenge to regulate.

    “Decentralized manufacturing in multiple small facilities is appealing, but new models of production scaling that rely on this approach remain a challenge to regulate (137-139).”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [137] Abou-El-Enein, 2016, Putting a price tag on novel autologous cellular therapies, Cytotherapy source
    • cites [138] U.S. Food and Drug Administration, 2008, Guidance for industry: CGMP for phase 1 investigational drugs

      Not checked in the free run.

    • cites [139] Elsallab, 2020, Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: a comparative study with other biologicals, Mol Ther Methods Clin Dev source

      The Discussion describes manufacturing and logistics constraints and regulatory objections for advanced therapies, but does not address decentralized production across multiple small facilities or the appeal and regulatory difficulty of scaling that model. Searches for decentralized manufacturing, scale-out, and multiple facilities found no passage making the attributed point; page numbers were unavailable in our copy. (LLM, conf=0.72)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Most CAR T cells for clinical trials and all commercial CAR T cells use viral vectors for genetic modification.

    “Most CAR T cells for clinical trials and all commercial CAR T cells use viral vectors for genetic modification (4-8) (Figure 3).”
    Quote in the paperNot a substantial claim0 of 5 sources checked
    • cites [4] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [5] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [6] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [7] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research

      Not checked in the free run.

    • cites [8] U.S. Food and Drug Administration, 2020, Center for Biologics Evaluation and Research

      Not checked in the free run.

  • May combine two claims.

    Premisenone given

    Significant batch-to-batch variability exists with autologous cells, and most current manufacturing protocols rely on open, manual processing steps susceptible to operator-introduced errors, contamination, and not easily amenable to scale-out.

    “Besides the challenges of obtaining pure and viable starting material, significant batch-to-batch variability exists with autologous cells. Most current manufacturing protocols rely on open, manual processing steps susceptible to operator-introduced errors, contamination, and not easily amenable to scale-out.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Interpretationreasoning

    Academic cell culture platforms require trained staff and stringent cleanroom environments, making them less desirable for commercial CAR T cell manufacturing intended for a large number of patients.

    “Despite their advantages in the academic setting, such platforms require trained staff and stringent cleanroom environments, making them less desirable for commercial CAR T cell manufacturing intended for a large number of patients.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    Developing allogeneic CAR T cell products may offer an off-the-shelf option once certain barriers are overcome.

    “Additionally, developing allogeneic CAR T cell products may offer an “off-the-shelf” option once certain barriers are overcome.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    By 2026, commercial CAR T cell therapies are expected to comprise the largest share of oncology drug sales in pediatric and young adult patients with acute lymphocytic leukemia (44%) and adults with diffuse large B-cell lymphoma (46%).

    “By 2026, commercial CAR T cell therapies are expected to comprise the largest share of oncology drug sales in pediatric and young adult patients with acute lymphocytic leukemia (ALL) (44%) and adults with diffuse large B-cell lymphoma (DLBCL) (46%) (20).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [20] Yip, 2018, The market for chimeric antigen receptor T cell therapies, Nat Rev Drug Discov source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisereasoning

    There has been a shift in both academia and industry to develop fully closed and automated manufacturing platforms with the potential for scaling.

    “As these therapies reach commercial viability, there has also been a shift in both academia and industry to develop fully closed and automated manufacturing platforms with the potential for scaling.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisereasoning

    Closed and automated manufacturing systems are expensive to purchase, use costly reagents and disposable culture sets, may have sole-source providers posing supply-chain risk, and each instrument can manufacture only one product at a time, so scaling requires operating parallel instruments.

    “While such systems lessen the need for extensive manual handling of the manufactured product, they are expensive to purchase, use costly reagents and disposable culture sets, and may have sole-source providers, which can pose a risk to the supply chain. In addition, each instrument can manufacture only one product at a time, thus, scaling production requires operating parallel instruments.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    A single unit of the G-Rex bioreactor can provide a 500 cm2 gas permeable surface area with 5 L media capacity, sufficient to expand large numbers of CAR T cells for clinical applications.

    “A single unit of this bioreactor can provide a 500 cm2 gas permeable surface area with 5 L media capacity, which is sufficient to expand large numbers of CAR T cells for clinical applications.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationnone given

    Automating the manufacturing process may improve process reproducibility and robustness, and potentially lower costs when efficiently employed in large-scale production.

    “Additionally, automating the manufacturing process may improve process reproducibility and robustness, and potentially lower costs when efficiently employed in large-scale production.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    When manufacturing genetically modified cell-based products, a general problem is the relatively low efficiency of stable gene transfer.

    “When manufacturing genetically modified cell-based products, a general problem is the relatively low efficiency of stable gene transfer.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Interpretationcitation

    An automated QC testing setup that produces real-time measurements of cell binding and killing may prove advantageous for continuous product quality monitoring during manufacturing.

    “An automated QC testing setup that produces real-time measurements of cell binding and killing allowing for continuous product quality monitoring during the manufacturing process, may prove advantageous (125).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [125] Yang, 2019, A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed B cell acute lymphoblastic leukemia, Blood source

  • May combine two claims.

    Premisecitation

    For CRISPR-Cas technology, there is extensive evidence on potential off-target effects when introducing mutations in undesired genomic loci, and induction of host immune responses upon administration.

    “Especially for CRISPR-Cas technology, there is extensive evidence on potential off-target effects when introducing mutations in undesired genomic loci (142), and induction of host immune responses upon administration (143).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [142] 2020, CFR - Code of Federal Regulations Title 21 - Food and Drugs

      Not checked in the free run.

    • cites [143] Gaspar Ernesto, 2020, Pharmaceutical manufacturing in the EU and the EU–US mutual recognition agreement, PDA J Pharm Sci Technol source

  • May combine two claims.

    Interpretationreasoning

    The traditional scale up model of drug manufacturing can be at least partially applied to allogeneic CAR T cell manufacturing, so it may offer a theoretical scaling advantage over the autologous model.

    “Since the traditional scale up model of drug manufacturing can at least be partially applied to allogeneic CAR T cell manufacturing, it may offer a theoretical scaling advantage over the autologous model.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationcitation

    The infusion of Sleeping Beauty-engineered T cells less than two days post-electroporation suggests they were infused without full characterization.

    “T cells engineered using Sleeping Beauty were infused less than two days post-electroporation, suggesting that the engineered T cells were infused without full characterization (NCT03579888).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites NCT03579888

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    Full GMP compliance is required for Phase I clinical trials in the European Union, which could be cumbersome for academic developments.

    “Full GMP compliance is required for Phase I clinical trials which could be cumbersome for academic developments (134).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [134] Abou-El-Enein, 2017, Strategies for derisking translational processes for biomedical technologies, Trends Biotechnol source

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.

    Interpretationnone given

    Broadly accepted levels of standardization for CAR T cell manufacturing will enable more rapid assessment by regulatory authorities and facilitate technology transfer.

    “Broadly accepted levels of standardization for CAR T cell manufacturing will enable a more rapid assessment by regulatory authorities and facilitate technology transfer.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    If the benefit-risk assessment is favorable, separate biologics licenses could be issued to individual sites to allow independent manufacturing at each site.

    “If the benefit-risk assessment is favorable, separate biologics licenses could be issued to individual sites to allow independent manufacturing at each site.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    If one-hour sterility testing is accepted by regulatory agencies, it would significantly accelerate product release and improve overall scalability.

    “Such an advancement, if accepted by regulatory agencies, would significantly accelerate product release and improve overall scalability.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Recent efforts have focused on reducing the duration of the CAR T cell expansion step, which in turn reduces vein-to-vein manufacturing time.

    “Recent efforts have focused on reducing the duration of the CAR T cell expansion step which, in turn, reduces vein-to-vein manufacturing time.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.

  • May combine two claims.

    Premisecitation

    In six patients with active CD19+ lymphoid malignancy infused with CAR T cells manufactured using the Sleeping Beauty system, median CAR expression upon infusion was 86% (range 19%-97%), resulting in anti-tumor effects and no clinically significant CRS.

    “Researchers at M.D. Anderson Cancer Center in collaboration with Ziopharm reported that six patients with active CD19+ lymphoid malignancy were infused with CAR T cells manufactured using this system. Median CAR expression upon infusion was 86% (range 19%-97%), resulting in anti-tumor effects and no clinically significant CRS.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [119] Schober, 2019, Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function, Nat Biomed Eng source

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationnone given

    None of the approaches discussed are mutually exclusive with the current model of autologous CAR T cell manufacturing.

    “None of the approaches discussed here are mutually exclusive with the current model of autologous CAR T cell manufacturing.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisenone given

    Regulatory expectations for genetically modified cell products include biodistribution studies, integration-site analysis, and establishing reliable off-target screening strategies with robust validation of pre-determined target sites.

    “Moreover, besides the need for biodistribution studies and integration-site analysis, regulatory expectations also include establishing reliable off-target screening strategies with a robust validation of pre-determined target sites to evaluate the extent of nuclease-induced off-target mutagenesis.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationnone given

    In a decentralized model, automated platforms could simplify workflow, increase process robustness, enable scalability, and reduce costs, while maintaining or improving efficacy of resulting CAR T cell products.

    “In such model, automated platforms could simplify the workflow, increase process robustness, enable scalability, and reduce costs, while maintaining or even improving the efficacy of the resulting CAR T cell products.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Interpretationnone given

    Considerable variability can hinder CAR T cell manufacturing.

    “As discussed earlier, considerable variability can hinder CAR T cell manufacturing.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The FDA recently discussed decentralized manufacturing, which entails product manufacturing according to the same protocol at different sites and analyzing pooled safety and efficacy data.

    “Recently, the FDA discussed decentralized manufacturing (140), which entails product manufacturing according to the same protocol at different sites and analyzing pooled safety and efficacy data.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [140] European Medicines Agency (EMA), 2017, Guidelines on good manufacturing practice specific to advanced therapy medicinal products

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    The fusion between reverse transcriptase and catalytically impaired Cas9 endonuclease might enable delivery of gene cassettes without double-strand breaks, which induces much lower off-target editing.

    “The emergence of new tools such as the fusion between reverse transcriptase and catalytically impaired Cas9 endonuclease might enable the delivery of gene cassettes without the need for double-strand breaks (DSB) which also induces much lower off-target editing (147).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [147] Marks, 2018, Balancing safety and innovation for cell-based regenerative medicine, N Engl J Med source

  • May combine two claims.

    Interpretationreasoning

    Decentralized manufacturing may require additional up-front validation time, but reductions in costs and lead time delays could eventually be realized through efficiency of logistics and the overall production process.

    “Although this may require additional time for up-front validation, reduction in costs and in lead time delays could eventually be realized through efficiency of logistics and the overall production process.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationnone given

    Products developed in smaller academic centers equipped with GMP laboratories could be used to treat patients at regional medical centers.

    “Products developed in smaller academic centers equipped with GMP laboratories could be used to treat patients at regional medical centers.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationnone given

    Allogeneic products may become the model of choice for products manufactured at scale in larger centralized commercial facilities, once the limitations discussed above can be overcome.

    “Allogeneic products, however, may become the model of choice for products manufactured at scale in larger centralized commercial facilities, once the limitations discussed above can be overcome.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    qPCR assays for the detection of mycoplasma are now standard and reduce assay time from 28 days to 1-2 days.

    “qPCR assays for the detection of mycoplasma are now standard and reduce assay time from 28 days to 1-2 days (124).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [124] Zhang, 2019, CD19-directed fast CART therapy for relapsed/refractory acute lymphoblastic leukemia: from bench to bedside, Blood source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The FDA has noted that a major issue in implementing decentralized manufacturing is having sufficient understanding of critical quality attributes to assure consistency of manufacture from site to site.

    “The FDA has noted that one of the major issues in the implementation of this model is having a sufficient understanding of the critical quality attributes of the product, so that the consistency of its manufacture can be assured from site to site.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [140] European Medicines Agency (EMA), 2017, Guidelines on good manufacturing practice specific to advanced therapy medicinal products

      Not checked in the free run.

48 of 48

  • The paper relies on this without support.

    The demand for CAR T cell therapies will continue to increase, including for solid tumors, making scalable manufacturing necessary.

    “As demand for CAR T cell therapies increases, particularly when therapies for solid tumors have reached commercial stages, developing manufacturing platforms that enable scaling while embracing the principles of “quality by design,” will be crucial.”

  • The paper relies on this without support.

    Cells from healthy donors have not been exposed to chemotherapies and are free of tumor cells.

    “Since cells from healthy donors have not been exposed to chemotherapies and are free of tumor cells, their quality is expected to be superior to those obtained from cancer patients.”

  • The paper relies on this without support.

    Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.

    “Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.”

  • The paper relies on this without support.

    Among QC parameters, sterility tests require the most time.

    “Of these parameters, the sterility tests require the most time.”

  • The paper relies on this without support.

    Currently, compendial product sterility tests take 14 days, and the fungal assay can take up to 42 days.

    “Currently, the compendial product sterility tests take 14 days, and the fungal assay can take up to 42 days.”

  • The paper relies on this without support.

    Anaerobic and aerobic enriched media testing that takes 7 days is recognized by the European Pharmacopeia as an alternative rapid test.

    “Anaerobic and aerobic enriched media testing that takes 7 days is recognized by the European Pharmacopeia as an alternative “rapid” test.”

  • The paper relies on this without support.

    The FDA does not formally recognize rapid tests.

    “However, the FDA does not formally recognize rapid tests.”

  • The paper relies on this without support.

    Most manufacturers characterize the final CAR T-cell product by flow cytometry, with many characterization panels currently in use.

    “Most manufacturers characterize the final CAR T-cell product by flow cytometry, with many characterization panels currently in use.”

  • The paper relies on this without support.

    Qualification and validation of the assay are required prior to obtaining a BLA, which is needed in the U.S. for commercial manufacturing.

    “Qualification and validation of the assay are required prior to obtaining a BLA, which is needed in the U.S for commercial manufacturing.”

  • The paper relies on this without support.

    Currently, each manufacturer specifies their own potency assay and develops specific parameters in agreement with regulatory agencies for their clinical grade product.

    “Currently, each manufacturer specifies their own potency assay and develops, in agreement with the regulatory agencies, specific parameters appropriate for the clinical grade product they manufacture.”

  • The paper relies on this without support.

    To date, there is no consensus on a potency assay or platform that can accurately predict clinical response to CAR T cell therapy.

    “To date, there is no consensus on a potency assay or platform that can accurately predict clinical response to CAR T cell therapy.”

  • The paper relies on this without support.

    Variable gene expression is unavoidable in current CAR T cell generation protocols owing to retro- and lentiviral vector integration.

    “While variable gene expression is unavoidable in current CAR T cell generation protocols owing to retro- and lentiviral vectors integration, variabilities in other manufacturing parameters can be better controlled by adopting “Quality by Design” (QBD) principles (Figure 4).”

  • The paper relies on this without support.

    Clinical-grade reagents add to overall costs but are necessary to ensure quality of administered CAR T cell products.

    “These reagents add to the overall costs but are necessary to ensure the quality of the administered CAR T cell products.”

  • The paper relies on this without support.

    Properly trained production and QC staff under GMP conditions is a key element in product manufacture.

    “Production and QC staff properly trained to work under GMP conditions is another key element in product manufacture.”

  • The paper relies on this without support.

    CIRM recognizes the need for training a GMP workforce and offers educational grants to train students on cell therapy manufacturing.

    “This need has also been recognized by the California Institute for Regenerative Medicine (CIRM), which offers educational grants to train students on cell therapy manufacturing.”

  • The paper relies on this without support.

    In the United States, the FDA requires demonstration of safety and substantial evidence of efficacy from clinical trials, and data from these trials are used to apply for a BLA.

    “In the United States, the FDA requires the demonstration of safety and substantial evidence of efficacy from clinical trials. Data from these trials are then used to apply for a Biologics License Application (BLA).”

  • The paper relies on this without support.

    For Phase 2 or 3 clinical trials, the FDA more tightly regulates the process.

    “For Phase 2 or 3 clinical trials, however, the FDA more tightly regulates the process.”

  • The paper relies on this without support.

    Gene-modified cellular products are subjected to greater regulatory scrutiny in the E.U. than non-gene modified therapies.

    “Also, gene-modified cellular products are subjected to greater regulatory scrutiny in the E.U. than non-gene modified therapies.”

  • The paper relies on this without support.

    Developers have been keen on setting up production facilities in the respective geographical areas to fully comply with the local regulatory landscape.

    “Therefore, developers have been keen on setting up production facilities in the respective geographical areas to fully comply with the local regulatory landscape.”

  • The paper relies on this without support.

    To increase accessibility of autologous CAR T cell products, some therapies in development are transitioning toward decentralized manufacturing.

    “To increase the accessibility of autologous CAR T cell products, some therapies in development are transitioning toward decentralized manufacturing.”

  • The paper relies on this without support.

    Novel approaches to shorten the manufacturing process are being developed, such as non-viral vector approaches relying on electroporation of primary cells.

    “Finally, novel approaches to shorten the manufacturing process are being developed, such as non-viral vector approaches relying on electroporation of primary cells.”
21 of 21

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Development of bioreactors and closed system manufacturing platforms mitigates the need for expensive infrastructure and simplifies the multistep CAR-T manufacturing process.

    “A paradigm shift enabling POC manufacturing is the development of bioreactors and closed system manufacturing platforms that mitigate the need for expensive infrastructure and simplify the multistep process.2,8,9”

    From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [8]

    The sections “Shifting from open to functionally closed systems” and “Replacing manual processing with automation” describe closed bioreactors and systems that reduce product handling and can operate in less stringent cleanrooms (page numbers unavailable). This supports some simplification and reduced cleanroom requirements, but not the unqualified claim that the platforms remove the need for expensive infrastructure: the paper says fill-finish still requires an ISO7 cleanroom and that the systems and reagents can be costly. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B.
Affiliations
  • 1Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • University of Southern California (US)
  • Stanford Cancer Institute (US)
  • University of Pennsylvania (US)
  • Houston Methodist (US)
  • Center for Biologics Evaluation and Research (US)
  • Fred Hutch Cancer Center (US)
  • University of California, Davis (US)
  • University of North Carolina at Chapel Hill (US)
ORCID
Venue
Blood Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Published
2021-08-03
Volume
2
Issue
5
Pages
408-422
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
DOI
10.1158/2643-3230.bcd-21-0084
PMC
PMC8462122
OpenAlex
W3190521604
Semantic Scholar
292a0bb64b8809ead2a11f9da2048d96231f0620
Cited by
321
References
143
Citations by year
2026: 79 · 2025: 81 · 2024: 81 · 2023: 37 · 2022: 41 · 2021: 2
FWCI
4.88
Type
journal article
Language
en
Open access
Locations
  • Blood Cancer Discovery (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • NCI (P50CA126752)
  • American Association for Cancer Research (SU2C-AACR-DT-29–19)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
chimeric antigen receptor T cells, chimeric antigen receptor, T cell manufacturing, scalable fabrication, good manufacturing practices, hematologic malignancies, production time reduction, regulatory challenges, production optimization
MeSH terms
Humans, Neoplasms, T-Lymphocytes, Reproducibility of Results, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review